On Friday, Xeris Biopharma Holdings Inc (NASDAQ: XERS) opened lower -1.14% from the last session, before settling in for the closing price of $1.76. Price fluctuations for XERS have ranged from $1.46 to $3.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 195.35%. Company’s average yearly earnings per share was noted 23.17% at the time writing. With a float of $125.56 million, this company’s outstanding shares have now reached $138.13 million.
Let’s determine the extent of company efficiency that accounts for 377 employees.
Xeris Biopharma Holdings Inc (XERS) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Xeris Biopharma Holdings Inc is 10.60%, while institutional ownership is 41.01%. The most recent insider transaction that took place on Mar 14 ’24, was worth 9,720. In this transaction Director of this company bought 4,500 shares at a rate of $2.16, taking the stock ownership to the 11,000 shares. Before that another transaction happened on Nov 27 ’23, when Company’s Director bought 5,400 for $1.87, making the entire transaction worth $10,098. This insider now owns 5,400 shares in total.
Xeris Biopharma Holdings Inc (XERS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.68 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.17% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Check out the current performance indicators for Xeris Biopharma Holdings Inc (XERS). In the past quarter, the stock posted a quick ratio of 1.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.49.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.11 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Looking closely at Xeris Biopharma Holdings Inc (NASDAQ: XERS), its last 5-days average volume was 1.65 million, which is a drop from its year-to-date volume of 2.19 million. As of the previous 9 days, the stock’s Stochastic %D was 10.47%. Additionally, its Average True Range was 0.11.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 3.18%, which indicates a significant decrease from 11.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.67% in the past 14 days, which was lower than the 71.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.4315, while its 200-day Moving Average is $2.2129. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $1.7833. Second resistance stands at $1.8267. The third major resistance level sits at $1.8733. If the price goes on to break the first support level at $1.6933, it is likely to go to the next support level at $1.6467. Should the price break the second support level, the third support level stands at $1.6033.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
There are currently 140,453K shares outstanding in the company with a market cap of 244.38 million. Presently, the company’s annual sales total 163,910 K according to its annual income of -62,260 K. Last quarter, the company’s sales amounted to 44,390 K and its income totaled -13,390 K.
